|
|
Volumn 32, Issue 14, 2014, Pages 1392-1393
|
|
How to interpret patient preferences in selecting the best drug: Are the current measurements up to the job?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PAZOPANIB;
SUNITINIB;
ANTINEOPLASTIC AGENT;
INDOLE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
PYRROLE DERIVATIVE;
SULFONAMIDE;
ASTHENIA;
CANCER CHEMOTHERAPY;
CANCER FATIGUE;
CANCER SURVIVAL;
DIARRHEA;
DRUG CHOICE;
DRUG EFFICACY;
DRUG NOMENCLATURE;
DRUG PREFERENCE;
DRUG SAFETY;
EDITORIAL;
GASTROINTESTINAL STROMAL TUMOR;
HUMAN;
INTENTION TO TREAT ANALYSIS;
KIDNEY CANCER;
METRIC SYSTEM;
PATIENT ASSESSMENT;
PATIENT CODING;
PATIENT DECISION MAKING;
PATIENT PREFERENCE;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SOFT TISSUE SARCOMA;
TREATMENT DURATION;
FEMALE;
KIDNEY CARCINOMA;
KIDNEY TUMOR;
MALE;
NOTE;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
FEMALE;
HUMANS;
INDOLES;
KIDNEY NEOPLASMS;
MALE;
PATIENT PREFERENCE;
PYRIMIDINES;
PYRROLES;
SULFONAMIDES;
|
|
EID: 84902831369
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2014.55.1911 Document Type: Editorial |
|
Times cited : (8)
|
|
References (4)
|
